

Protokollen med vedlegg er utarbeidet både på norsk og engelsk. Ved uoverensstemmelser mellom de to versjonene, skal den norske versjonen ha forrang.

**PROTOKOLL FRA EKSTRAORDINÆR
GENERALFORSAMLING I IDEX BIOMETRICS
ASA**

(org.nr. 976 846 923)

Det ble avholdt ekstraordinær generalforsamling i Idex Biometrics ASA («Selskapet») den **11. april 2025 kl. 12:00 (CET)**. Generalforsamlingen ble gjennomført som et elektronisk møte. Generalforsamlingen ble åpnet av Morten Opstad.

Tilstede: 44 aksjonærer var tilstede fysisk, gjennom den elektroniske løsningen eller ved fullmakt, som totalt representerte 268 077 252 aksjer. Dette utgjorde 32,24 % av aksjekapitalen i Selskapet.

Oversikt over stemmeberettigede aksjer representert, protokoll for stemmegivningen og fortegnelse over deltakende aksjonærer vedlegges.

1. Registrering av deltakende aksjonærer; Valg av møteleder og en person til å medundertegne protokollen

Morten Opstad gjennomgikk fremlagt online oppmøteliste, fullmaktliste og oversikt over stemmeinstrukser fra DNB Bank ASA Verdipapirservice. Denne ble vedtatt og lagt til grunn. Stemmeresultatet fremgår av protokollen.

Generalforsamlingen fattet følgende vedtak:

Morten Opstad ble valgt til møteleder. Kristian Flaten ble valgt til å medundertegne protokollen.

2. Godkjenning av møteinnkalling og dagsorden

Det kom ingen innvendinger mot innkallingen, som sammen med dagsorden ble godkjent av generalforsamlingen. Stemmeresultatet fremgår av protokollen.

3. Kapitalnedsettelse ved reduksjon av aksjenes pålydende (herunder godkjenning av mellombalanse) og endring av Selskapets vedtekter

The minutes with attachments have been prepared in both Norwegian and English. In case of any discrepancy between the two versions, the Norwegian version shall prevail.

**MINUTES FROM EXTRAORDINARY
GENERAL MEETING IN IDEXBIOMETRICS
ASA**

(org.no. 976 846 923)

An Extraordinary General Meeting was held in Idex Biometrics ASA (the "Company") on **11 April 2025 at 12:00 hours (CET)**. The general meeting was held as an electronic meeting. The general meeting was opened by Morten Opstad.

Present: 44 shareholders were present in person, electronically or by way of proxy, representing in total 268,077,252 shares. This amounted to 32.24 % of the share capital of the Company.

An overview of the represented shares entitled to vote, the record of votes cast, and the register of participating shareholders, are set out in these minutes.

1. Registration of participating shareholders; election of a person to chair the Meeting and a person to co-sign the minutes

Morten Opstad reviewed the submitted online attendance list, the list of proxies and the list of voting instructions from DNB Bank ASA, Registrars Department. The list was resolved and admitted. The voting results are set out in these minutes.

The general meeting passed the following resolution:

Morten Opstad was elected to chair the meeting. Kristian Flaten was elected to co-sign the minutes.

2. Approval of the notice and the agenda of the Meeting

The notice and the agenda were approved by the general meeting. The voting results are set out in these minutes.

3. Reduction of share capital by reduction of par value of the shares (including approval of interim balance sheet) and amendment of the Company's Articles of Association

Styrets forslag ble gjennomgått og vedtatt. Stemmeresultatet fremgår av protokollen. Generalforsamlingen fattet følgende <u>vedtak:</u> 3.1 Godkjenning av mellombalanse <i>Selskapets mellombalanse per 1. januar 2025, som inntatt i Vedlegg 1 til denne protokollen, godkjennes.</i> 3.2 Kapitalnedsettelse ved reduksjon av aksjenes pålydende <i>1. Aksjekapitalen settes ned fra NOK 124 739 134,80 til NOK 8 315 942,32 ved reduksjon av aksjenes pålydende fra NOK 0,15 per aksje med NOK 0,14 per aksje til NOK 0,01 per aksje.</i> <i>2. Nedsettingsbeløpet er i sin helhet innbetalt kapital og skal fullt ut benyttes til dekning av tap som ikke kan dekkes på annen måte, jf. allmennaksjeloven § 12-1 første ledd nr. 1. Kapitalnedsettelsen medfører ingen utdeling.</i> <i>3. Beregningen av Selskapets tap er foretatt på grunnlag av en mellombalanse i Selskapet per 1. januar 2025.</i> 3.3 Endring av Selskapets vedtekter Punkt 5 i Selskapets vedtekter endres til å lyde: <i>"Selskapets aksjekapital er 8 315 942,32 fordelt på 831 594 232 aksjer á NOK 0,01 lydende på navn."</i> 4. Kapitalforhøyelse ved gjeldskonvertering; Utstedelse av nye aksjer og endring av vedtektene Styrets forslag ble gjennomgått og vedtatt. Stemmeresultatet fremgår av protokollen. Generalforsamlingen fattet følgende <u>vedtak:</u> 4.1 Utstedelse av nye aksjer <i>a) Aksjekapitalen økes fra NOK 8 315 942,32 med NOK 30 000 000,00 til NOK 38 315 942,32 ved utstedelse av 3</i>	The Board's proposal was reviewed and approved. The voting results are set out in these minutes. The general meeting passed the following <u>resolutions:</u> 3.1 Approval of interim balance sheet <i>The Company's interim balance sheet as of 1 January 2025, as attached in Appendix 1 to these minutes, is approved.</i> 3.2 Reduction of share capital by reduction of par value of the shares <i>1. The share capital is reduced from NOK 124,739,134.80 to NOK 8,315,942.32 by reduction of the par value per share from NOK 0.15 per share by NOK 0.14 per share to NOK 0.01 per share.</i> <i>2. The reduction amount is in whole paid-in capital and shall wholly be used for coverage of loss that cannot be covered otherwise, in accordance with Section 12-1 (1) no. 1 of the PLCA. The share capital reduction does not cause any distribution.</i> <i>3. The calculation of the Company's losses has been made based on the Company's interim balance sheet in the Company as of 1 January 2025.</i> 3.3 Amendment of Articles of Association Section 5 in the Company's Articles of Association shall be amended to read as follows: <i>"The Company's share capital is NOK 8,315,942.32 divided into 831,594,232 shares with a nominal value of NOK 0.01 per share and issued in name. "</i> 4. Share capital increase by conversion of debt; Issuance of new shares and amendment of articles of association The Board's proposal was reviewed and approved. The voting results are set out in these minutes. The general meeting passed the following <u>resolutions:</u> 4.1 Issuance of new shares <i>a) The share capital is increased from NOK 8,315,942.32 by NOK 30,000,000.00 to NOK</i>
---	---




000 000 000 nye aksjer pålydende NOK 0,01 pr. aksje til tegningskurs NOK 0,01 pr. aksje. Samlet tegningsbeløp er NOK 30 000 000,00, hvorav alt utgjør aksjekapital.

b) De nye aksjene tegnes av tegnerne angitt i Vedlegg 2 til protokollen fra EGF.

c) De eksisterende aksjonærenes fortrinnsrett fravikes.

d) Aksjene tegnes på særskilt tegningsblankett innen 22. april 2025 eller slik senere dato fastsatt av styret, men ikke senere enn 2. mai 2025.

e) Aksjeinnskuddet skal gjøres opp umiddelbart etter tegning ved motregning av fordringer på til sammen NOK 30 000 000,00 som aksjetegnerne har mot Selskapet. For nærmere beskrivelse av innskuddet vises det til sakkyndig redegjørelse.

f) De nye aksjene gir rett til utbytte og rettigheter for øvrig fra og med kapitalforhøyelsens registrering i Foretaksregisteret.

g) Utgiftene til kapitalforhøyelsen er anslått til ca. NOK 600 000, som inkluderer utgifter til utarbeidelse av prospekt, samt prospektgebyr. Utgiftene dekkes av Selskapet.

Avskrift av seneste årsregnskap, årsberetning og revisjonsberetning er utlagt på Selskapets kontor.

Opptak av Lånet og den foreslåtte gjennomføringen av Gjeldskonverteringen, Kapitalnedsettelsen og aksjespleisen, godkjenning av det Konvertible Lånet (som heretter definert), og endringen i Selskapets forretningsstrategi og ledelse (som annonsert av Selskapet den 11. mars 2025) er alle hendelser etter siste balansedag som er ansett å være av vesentlig betydning for Selskapet. Utenom dette har det ikke inntruffet hendelser etter siste balansedag som er av vesentlig betydning for Selskapet.

4.2 Endring av Selskapets vedtekter

38,315,942.32 by issuance of 3,000,000,000 new shares with a nominal value of NOK 0.01 per share, at a subscription price of NOK 0.01 per share. The total subscription amount is NOK 30,000,000.00, all of which is share capital.

b) The new shares shall be subscribed for by the subscribers stated in Appendix 2 to the minutes from the EGM.

c) The current shareholders' preferential rights is deviated from.

d) The shares shall be subscribed to on a separate subscription form within 22 April 2025, or such later date as determined by the Board, but no later than 2 May 2025.

e) The subscription amount shall be settled immediately upon subscription by set off against the total claims of NOK 30,000,000.00 which the subscribers have against the Company. For further details regarding the contribution, reference is made to the expert statement.


f) The new shares grant dividend rights and other rights from the time when the share capital increase has been registered in the Business Register.

g) The cost of the capital increase is estimated to approximately NOK 600,000, which includes fees for the preparation of a prospectus and the prospectus fee. The costs shall be paid by the Company.

Copies of the latest annual accounts, the annual report and the auditor's report is available at the Company's offices.

The obtaining of the Loans and the proposed performing of the Debt Conversion, Share Capital Reduction and share consolidation, approval of the Convertible Loans (as hereinafter defined), and change of business strategy and executive management in the Company (as announced by the Company on 11 March 2025), are all considered events since the latest balance date which is deemed to significantly impact the Company. Other than this, there have not been any events since the latest balance date which significantly impacts the Company.

4.2 Amendment of the Company's Articles of Association



Punkt 5 i Selskapets vedtekter endres til å lyde:

"Selskapets aksjekapital er 38 315 942,32 fordelt på 3 831 594 232 aksjer á NOK 0,01 lydende på navn."

5. Reparasjonsemisjon og vedtektsendring

Styrets forslag ble gjennomgått og vedtatt. Stemmeresultatet fremgår av protokollen. Generalforsamlingen fattet følgende

vedtak:

1. Selskapets aksjekapital kan forhøyes med opptil NOK 6 000 000 ved utstedelse av opptil 600 000 000 aksjer i en Reparasjonsemisjon, hver aksje pålydende NOK 0,01, til tegningskurs per aksje tilsvarende tegningskurs per aksje i Gjeldskonverteringen, dvs. NOK 0,01.

2. De nye aksjene kan tegnes av aksjeeiere i Selskapet per datoen for opptak av Lånet, den 10. mars 2025 i henhold til Selskapets aksjeeierregister i VPS den 12. mars 2025 («**Record Date**»), som (i) ikke deltok i Lånet og som ikke ble tildelt nye aksjer i Gjeldskonverteringen, og som (ii) ikke er hjemmehørende i en jurisdiksjon hvor slik tildeling ville være ulovlig eller, for andre jurisdiksjoner enn Norge, ville påkrevne prospekt, søknad, registrering eller lignende handling («**Berettigede Aksjeeiere**»). Berettigede Aksjeeiere vil tildeles tegningsretter som gir fortrinnsrett til å tegne aksjer i Reparasjonsemisjonen. Berettigede Aksjeeiere tildeles et forholdsmessig antall tegningsretter sammenlignet med antallet aksjer i Selskapet som den Berettigede Aksjeeier er registrert som eier av på Record Date. En rett til å tegne for en del av en aksje skal rundes ned til nærmeste hele aksje. Overtegning er tillatt, men tegning uten tegningsrett er ikke tillatt. Overtegning og ubenyttede tegningsretter fordeles slik som fastsatt av styret i henhold til kriterier som vil angis i et prospekt godkjent av Finanstilsynet i henhold til kapittel 7 i verdipapirloven og offentliggjort før ikrafttredelsen av tegningsperioden i Reparasjonsemisjonen («**Prospektet**»). Med mindre styret beslutter noe annet, skal Prospektet ikke registreres eller godkjennes av myndigheter utenfor Norge. Tegningsrettene kan ikke overdras, og vil ikke bli tatt opp til handel på Oslo Børs.

Section 5 in the Company's Articles of Association shall be amended to read as follows:

"The Company's share capital is NOK 38,315,942.32 divided into 3,831,594,232 shares with a nominal value of NOK 0.01 per share and issued in name. "

5. Subsequent offering and amendment of the articles of association

The Board's proposal was reviewed and approved. The voting results are set out in these minutes. The general meeting passed the following

resolution:

1. The Company's share capital may be increased with up to NOK 6,000,000, by issuance of up to 600,000,000 shares in a Subsequent Offering, each share having a par value of NOK 0.01, for a subscription price per share equal to the subscription price per share in the Debt Conversion, being NOK 0.01.

2. The new shares may be subscribed for by shareholders in the Company as per the date of the undertaking of the Loans as of 10 March 2025 (as registered in the Norwegian Central Securities Depository ("VPS") on 12 March 2025) (the "**Record Date**"), who (i) did not participate in the Loans, and are not allocated new shares in the Debt Conversion and (ii) are not resident in a jurisdiction where such offering would be unlawful or, for jurisdictions other than Norway, would require any prospectus, filing, registration or similar action ("**Eligible Shareholders**"). Eligible Shareholders will be granted subscription rights that give preferential rights to subscribe for shares in the Subsequent Offering. Eligible Shareholders shall receive subscription rights proportionate to the number of shares in the Company that are registered as held by such Eligible Shareholder on the Record Date. A right to subscribe for a fraction of a share shall be rounded down to the nearest whole share. Oversubscription is permitted, but subscription without subscription rights is not permitted. Oversubscription and unexercised subscription rights will be allocated as determined by the Board pursuant to criteria to be set out in a prospectus to be approved by the Norwegian Financial Supervisory Authority of Norway (the "**FSA**") pursuant to chapter 7 of the Norwegian Securities Trading Act and published prior to the commencement of the subscription period in the Subsequent Offering (the "**Prospectus**"). Unless the Board decides otherwise, the Prospectus shall not be registered with or be approved by authorities outside

3. Nåværende aksjeeieres fortrinnsrett etter allmennaksjeloven § 10-4 fravikes. 4. Tegningsperioden for Reparasjonsemissjonen starter den 12. mai 2025 og utløper den 26. mai 2025 klokken 16:30 (norsk tid) (eller en slik senere dato som fastsettes av styret, men tegningsperioden skal starte senest den 2. juni 2025 og utløpe den 16. juni 2025. Dersom Finanstilsynet per utgangen av 11. mai 2025 ikke har godkjent Prospektet, skal tegningsperioden starte den første handelsdagen på Oslo Børs etter at Prospektet er godkjent, senest 2. juni 2025, og avsluttes klokken 16:30 (norsk tid) 14 kalenderdager deretter. Nærmere kriterier for tegningen fastsettes av styret og vil bli beskrevet i Prospektet. 5. Tegningskurs skal betales innen fem (5) dager etter utløpet av tegningsperioden. Tegnere som er hjemmehørende i Norge, må ved påtegning av tegningsblanketten gi Arctic Securities AS en ugjenkallelig engangsfullmakt til å belaste en oppgitt bankkonto i Norge for det beløp som skal betales for tildelte aksjer til tegneren. Belasting av konto vil foretas på eller rundt fristen for betaling av tegningskursen. For tegnere uten norsk bankkonto skal betaling skje i henhold til instruksjoner inntatt i tegningsblanketten vedlagt Prospektet. 6. De nye aksjene skal gi rett til utbytte eller andre utdelinger som fastsettes etter registreringen av kapitalforhøyelsen i Foretaksregisteret. Kostnadene ved kapitalforhøyelsen vil bero på totalt antall aksjer som tegnes i Reparasjonsemissjonen. Kostnadene er estimert til å utgjøre opptil NOK 400 000, inkludert kostnader til rådgivere, men ekskludert kostnader tilknyttet utarbeidelse av prospekt (slike kostnader er angitt og medtatt i agendapunkt 4.1). 7. Etter at Reparasjonsemissjonen er fullført, har styret kompetanse til å endre punkt 5 i Selskapets vedtekter for å fastsette Selskapets aksjekapital og antallet aksjer etter Reparasjonsemissjonen. 8. Styret kan når som helst før gjennomføring velge å kansellere Reparasjonsemissjonen dersom gjeldende markedsforhold tilsier en slik kansellering (herunder dersom tegningskursen er høyere enn markedspris).	Norway. The subscription rights are non-transferable and will not be admitted for trading on Oslo Børs. 3. The existing shareholders' preferential rights pursuant to Section 10-4 of the PLCA is deviated from. 4. The subscription period for the Subsequent Offering will commence on 12 May 2025 and end on 26 May 2025 at 16:30 hrs (CET) (or at such later date as determined by the Board, but not later than commencing 2 June 2025 and ending on 16 June 2025. In the event that the Prospectus has not been approved by the FSA by the end of 11 May 2025, the subscription period will commence on the first trading day on Oslo Børs following FSA approval and no later than 2 June 2025 and end at 16:30 hrs (CET) 14 calendar days later. The more detailed criteria for subscription will be determined by the Board and described in the Prospectus. 5. Payment of the subscription price shall be made within five (5) days after the expiration of the subscription period. When completing the subscription form, each subscriber domiciled in Norway shall provide a one-time irrevocable authorization to Arctic Securities AS to debit a specific bank account with a Norwegian bank for the amount payable for the shares allocated to the subscriber. The debiting will be done on or about the deadline for payment. For subscribers without a Norwegian bank account, payment shall be made pursuant to the instructions included in the subscription form attached to the Prospectus. 6. The new shares shall carry right to dividend or other distributions that are declared following registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). The costs related to the share capital increase will depend on the total subscription in the Subsequent Offering. Such costs are estimated to amount to up to NOK 400,000, including fees to advisors, but excluding costs related to the preparation of a prospectus (such costs are stated and included in agenda item 4.1). 7. Following completion of the Subsequent Offering, the Board is authorized to amend Section 5 of the Articles of Association to state the share capital and number of shares following the Subsequent Offering. 8. The Board may at any time prior to completion determine to cancel the Subsequent Offering in case applicable market terms provide grounds for such a cancellation (including if the subscription price exceeds the market price).
---	--

6. Styrefullmakt til å utstede nye aksjer

Styrets forslag ble gjennomgått og vedtatt. Stemmeresultatet fremgår av protokollen. Generalforsamlingen fattet følgende separate

vedtak:

(a) Styrefullmakt til å utstede aksjer ved private plasseringer

1. Styret i IDEX Biometrics ASA ("Selskapet") gis fullmakt til å gjennomføre én eller flere kapitalutvidelser ved å utstede nye aksjer. Aksjekapitalen kan etter denne fullmakt økes med inntil NOK 4 431 594,23 (som tilsvarer 10 prosent av Selskapets aksjekapital, forutsatt at Kapitalnedsettelsen foreslått i agendapunkt 3, Gjeldskonverteringen foreslått i agendapunkt 4, og Reparasjonsemisjonen foreslått i agendapunkt 5 gjennomføres). Videre skal summen av kapitalutvidelsene som styret kan gjennomføre under dette punkt 6 underpunkt (a) og (b) under enhver omstendighet ikke overstige summen som utgjør 10 prosent av Selskapets registrerte aksjekapital på tidspunktet for styrets beslutning. Alle tidligere fullmakter som er gitt styret til å utstede aksjer skal trekkes tilbake med virkning fra tidspunktet for registrering av nærværende fullmakt i Foretaksregisteret (ikke inkludert de øvrige fullmaktene på dagsorden og agendapunkt 8.1 i protokollen fra ordinær generalforsamling i 2024).

2. Denne fullmakten kan benyttes i forbindelse med private plasseringer og utstedelse av aksjer til egnede investorer (kan være nåværende og/eller nye aksjeeiere, herunder ansatte i Selskapet) for å innhente ytterligere kapital for Selskapet. Fullmakten dekker ikke kapitalutvidelser i forbindelse med fusjoner, jf. allmennaksjeloven § 13-5.

3. Dersom Selskapets aksjekapital eller pålydende per aksje endres ved fondsemissjon, aksjesplitt, aksjespleis, kapitalnedsettelse ved reduksjon av pålydende osv., skal den maksimale nominelle verdi av aksjene som utstedes under denne fullmakt, justeres tilsvarende (likevel slik at dette ikke skal gjelde agendapunktene på denne EGF).

4. Nåværende aksjeeiere gir avkall på sine fortrinnsretter til å tegne aksjer i medhold av

6. Authorizations to the Board to issue new shares

The Board's proposal was reviewed and approved. The voting results are set out in these minutes. The general meeting passed the following separate

resolutions:

(a) Board authorization to issue shares in private placements

1. The Board of Directors of IDEX Biometrics ASA (the "Company") is authorized to accomplish one or more share capital increases by issuing new shares. The total amount by which the share capital may be increased is NOK 4,431,594.23 (representing 10 per cent of the share capital of the Company, assuming that the Share Capital Reduction proposed in agenda item 3, the Debt Conversion proposed in agenda item 4, and the Subsequent Offering proposed in agenda item 5 are carried out). Moreover, under no circumstances shall the sum of capital increases that may be accomplished by the Board collectively under agenda item 6 subitems (a) and (b) exceed a sum equivalent to 10 per cent of the Company's registered share capital at the time of the Board's resolution. Any previous authorizations given to the Board to issue shares shall be, and hereby are, withdrawn with effect from the date this authorization is registered in the Register of Business Enterprises (not including the other authorizations contained in this agenda, the resolutions in agenda item 8.1 in the minutes from the 2024 Annual General Meeting.).

2. The authorization may be used in connection with private placements and share issues to suitable investors (may be existing and/or new shareholders, hereunder employees in the Company) in order to raise additional capital for the Company. The authorization does not comprise share capital increases in connection with mergers, cf. Section 13-5 of the PLCA.

3. In the event the Company's share capital or nominal value per share is changed by way of a capitalization issue, share split, reverse share split, share capital reduction by way of reduction of the par value etc., the maximum nominal value of the shares that may be issued under this authorization shall be adjusted accordingly (however so that this shall not apply to the agenda items on this EGM).

4. Existing shareholders are waiving their pre-emptive right to subscribe for shares according to the

allmennaksjeloven i tilfelle en forhøyelse av aksjekapitalen ifølge denne fullmakt.

5. Styret har fullmakt til å fastsette vilkår for tegningen, herunder tegningskurs, dato for innbetaling og retten til videresalg av aksjene til andre.

6. Betaling av aksjekapital i forbindelse med en kapitalforhøyelse som det er gitt fullmakt til her, kan foretas ved tingsinnskudd og på andre måter som beskrevet i allmennaksjeloven § 10-2.

7. Den ekstraordinære generalforsamlingen gir styret fullmakt til å endre Selskapets vedtekter vedrørende størrelsen på aksjekapitalen og antall utestående aksjer når den nærværende fullmakten brukes.

8. Fullmakten skal gjelde frem til det tidspunktet erstattende fullmakt er registrert i Foretaksregisteret, og uansett ikke senere enn 30. juni 2025.

9. De nye aksjene som kan tegnes ifølge denne fullmakten, skal være berettiget til utbytte som besluttet utdelt etter at tegningskursen er innbetalt og kapitalforhøyelsen er registrert i Foretaksregisteret. I andre henseender skal aksjene ha aksjeeierrettigheter fra den dagen de blir utstedt, med mindre styret bestemmer noe annet.

10. Aksjer som ikke er fullt innbetalt kan ikke overdras eller selges.

(b) Styrefullmakt til å utstede aksjer ved fortrinnsrettsemisjoner

1. Styret i IDEX Biometrics ASA ("Selskapet") gis fullmakt til å gjennomføre én eller flere kapitalutvidelser ved å utstede nye aksjer. Aksjekapitalen kan etter denne fullmakt økes med inntil NOK 4 431 594,23 (som tilsvarer 10 prosent av Selskapets aksjekapital, forutsatt at Kapitalnedsettelsen foreslått i agendapunkt 3, Gjeldskonverteringen foreslått i agendapunkt 4, og Reparasjonsemisjonen foreslått i agendapunkt 5 gjennomføres). Videre skal summen av kapitalutvidelsene som styret kan gjennomføre under dette punkt 6 underpunkt (a) og (b) under enhver omstendighet ikke overstige summen som utgjør 10 prosent av Selskapets registrerte aksjekapital på tidspunktet for styrets beslutning. Alle tidligere fullmakter som er gitt styret til å utstede aksjer skal trekkes tilbake med virkning fra tidspunktet for

PLCA in the event of a share capital increase as authorized herein.

5. The Board is authorized to decide upon the subscription terms, including issue price, date of payment and the subscribers' right to sell shares to others.

6. Payment of share capital in connection with a share capital increase authorized herein may be made by way of non-cash contribution and other special subscription terms, as same are provided in Section 10-2 of the PLCA.

7. The Extraordinary General Meeting authorizes the Board to amend the Company's Articles of Association concerning the size of the share capital and number of outstanding shares when the instant authorization is used.

8. The authorization shall be valid until a replacing authorization has been registered in the Register of Business Enterprises, but not later than 30 June 2025.

9. The new shares, which may be subscribed for according to this authorization, shall have right to dividends declared subsequent to the subscriber having paid the subscription price and the associated share capital increase having been registered in the Register of Business Enterprises. In other respects, the shares shall have shareholder rights from the time of issuance, unless the Board determines otherwise.

10. Shares that are not fully paid cannot be transferred or sold.

(b) Board authorization to issue shares in rights issues

1. The Board of Directors of IDEX Biometrics ASA (the "Company") is authorized to accomplish one or more share capital increases by issuing new shares. The total amount by which the share capital may be increased is NOK 4,431,594.23 (representing 10 per cent of the share capital of the Company, assuming that the Share Capital Reduction proposed in agenda item 3, the Debt Conversion proposed in agenda item 4, and the Subsequent Offering proposed in agenda item 5 are carried out). Moreover, under no circumstances shall the sum of capital increases that may be accomplished by the Board collectively under agenda item 6 subitems (a) and (b) exceed a sum equivalent to 10 per cent of the Company's registered share capital at the time of the

registrering av nærværende fullmakt i Foretaksregisteret (ikke inkludert de øvrige fullmaktene på dagsorden, og agendapunkt 8.1 i protokollen fra ordinær generalforsamling i 2024). 2. Denne fullmakten kan benyttes i forbindelse med fortrinnsrettsemisjon mot eksisterende aksjonærer i Selskapet for å innhente ytterligere kapital for Selskapet. Fullmakten dekker ikke kapitalutvidelser i forbindelse med fusjoner, jf. allmennaksjeloven § 13-5. 3. Dersom Selskapets aksjekapital eller pålydende per aksje endres ved fondsemisjon, aksjesplitt, aksjespleis, kapitalnedsettelse ved reduksjon av pålydende osv., skal den maksimale nominelle verdi av aksjene som utstedes under denne fullmakt, justeres tilsvarende (likevel slik at dette ikke skal gjelde agendapunktene på denne EGF). 4. Styret har fullmakt til å fastsette vilkår for tegningen, herunder tegningskurs, dato for innbetaling og retten til videresalg av aksjene til andre. 5. Betaling av aksjekapital i forbindelse med en kapitalforhøyelse som det er gitt fullmakt til her, kan foretas ved tingsinnskudd og på andre måter som beskrevet i allmennaksjeloven § 10-2. 6. Den ekstraordinære generalforsamlingen gir styret fullmakt til å endre Selskapets vedtekter vedrørende størrelsen på aksjekapitalen og antall utestående aksjer når den nærværende fullmakten brukes. 7. Fullmakten skal gjelde frem til det tidspunktet erstattende fullmakt er registrert i Foretaksregisteret, og uansett ikke senere enn 30. juni 2025. 8. De nye aksjene som kan tegnes ifølge denne fullmakten, skal være berettiget til utbytte som besluttes utdelt etter at tegningskursen er innbetalt og kapitalforhøyelsen er registrert i Foretaksregisteret. I andre henseender skal aksjene ha aksjeeierrettigheter fra den dagen de blir utstedt, med mindre styret bestemmer noe annet.	Board's resolution. Any previous authorizations given to the Board to issue shares shall be, and hereby are, withdrawn with effect from the date this authorization is registered in the Register of Business Enterprises (not including the other authorizations contained in this agenda, the resolutions in agenda item 8.1 in the minutes from the 2024 Annual General Meeting). 2. The instant authorization may be used in connection with rights issue to existing shareholders of the Company in order to raise additional capital for the Company. The authorization does not comprise share capital increases in connection with mergers, cf. Section 13-5 of the PLCA. 3. In the event the Company's share capital or nominal value per share is changed by way of a capitalization issue, share split, reverse share split, share capital reduction by way of reduction of the par value etc., the maximum nominal value of the shares that may be issued under this authorization shall be adjusted accordingly (however so that this shall not apply to the agenda items on this EGM). 4. The Board is authorized to decide upon the subscription terms, including issue price, date of payment and the subscribers' right to sell shares to others. 5. Payment of share capital in connection with a share capital increase authorized herein may be made by way of non-cash contribution and other special subscription terms, as same are provided in Section 10-2 of the PLCA. 6. The Extraordinary General Meeting authorizes the Board to amend the Company's Articles of Association concerning the size of the share capital and number of outstanding shares when the instant authorization is used. 7. The authorization shall be valid until a replacing authorization has been registered in the Register of Business Enterprises, but not later than 30 June 2025. 8. The new shares, which may be subscribed for according to this authorization, shall have right to dividends declared subsequent to the subscriber having paid the subscription price and the associated share capital increase having been registered in the Register of Business Enterprises. In other respects, the shares shall have shareholder rights from the time of issuance, unless the Board determines otherwise.
--	--




9. Aksjer som ikke er fullt innbetalt, kan ikke overdras eller selges.

7. Styrefullmakt til å utstede nye aksjer til ansatte og konsulenter

Styrets forslag ble gjennomgått og vedtatt. Stemmeresultatet fremgår av protokollen. Generalforsamlingen fattet følgende

vedtak:

1. Styret i IDEX Biometrics ASA ("Selskapet") gis fullmakt til å gjennomføre én eller flere kapitalutvidelser ved å utstede nye aksjer til ansatte, konsulenter og styremedlemmer i Selskapet og dets datterselskaper. Fullmakten betinges av at Kapitalnedsettelsen foreslått i agendapunkt 3 og Gjeldskonverteringen foreslått i agendapunkt 4 godkjennes av EGF. Aksjekapitalen kan etter denne fullmakt økes med inntil NOK 3 000 000. Denne styrefullmakten er i tillegg til øvrige styrefullmakter i denne protokollen og i punkt 8.1 i protokollen fra ordinær generalforsamling i 2024.

2. Denne fullmakten kan benyttes i forbindelse med utstedelse av nye aksjer til ansatte, konsulenter og styremedlemmer i Selskapet og dets datterselskaper. Fullmakten dekker ikke kapitalutvidelser i forbindelse med fusjoner, jf. allmennaksjeloven § 13-5.

3. Dersom Selskapets aksjekapital eller pålydende per aksje endres ved fondsemisjon, aksjesplitt, aksjespleis, kapitalnedsettelse ved reduksjon av pålydende osv., skal den maksimale nominelle verdi av aksjene som utstedes under denne fullmakt, justeres tilsvarende (likevel slik at dette ikke skal gjelde agendapunktene på denne EGF).

4. Styret har fullmakt til å fastsette vilkår for tegningen, herunder tegningskurs, dato for innbetaling og retten til videresalg av aksjene til andre.

5. Betaling av aksjekapital i forbindelse med en kapitalforhøyelse som det er gitt fullmakt til her, kan foretas ved tingsinnskudd og på andre måter som beskrevet i allmennaksjeloven § 10-2.

9. Shares that are not fully paid cannot be transferred or sold.

7. Authorizations to the Board to issue new shares to employees and contractors

The Board's proposal was reviewed and approved. The voting results are set out in these minutes. The general meeting passed the following

resolution:

1. The Board of Directors of IDEX Biometrics ASA (the "Company") is authorized to accomplish one or more share capital increases by issuing new shares to employees, contractors and directors in the Company and its subsidiaries. The authorization is conditional upon the Share Capital Reduction proposed in item 3, and the Debt Conversion proposed in item 4, being approved by the EGM. The total amount by which the share capital may be increased is NOK 3,000,000. This Board authorization is in addition to the other Board authorizations in these minutes and in section 8.1 in the minutes from the 2024 Annual General Meeting.

2. The instant authorization may be used in connection with the issuance of new shares to employees, contractors and directors of the Company and its subsidiaries. The authorization does not comprise share capital increases in connection with mergers, cf. Section 13-5 of the PLCA.

3. In the event the Company's share capital or nominal value per share is changed by way of a capitalization issue, share split, reverse share split, share capital reduction by way of reduction of the par value etc., the maximum nominal value of the shares that may be issued under this authorization shall be adjusted accordingly (however so that this shall not apply to the agenda items on this EGM).

4. The Board is authorized to decide upon the subscription terms, including issue price, date of payment and the subscribers' right to sell shares to others.

5. Payment of share capital in connection with a share capital increase authorized herein may be made by way of non-cash contribution and other special subscription terms, as same are provided in Section 10-2 of the PLCA.



6. Den ekstraordinære generalforsamlingen gir styret fullmakt til å endre Selskapets vedtekter vedrørende størrelsen på aksjekapitalen og antall utestående aksjer når den nærværende fullmakten brukes. 7. Fullmakten skal gjelde frem til 14. juni 2025. 8. De nye aksjene som kan tegnes ifølge denne fullmakten, skal være berettiget til utbytte som besluttes utdelt etter at tegningskursen er innbetalt og kapitalforhøyelsen er registrert i Foretaksregisteret. I andre henseender skal aksjene ha aksjeeierrettigheter fra den dagen de blir utstedt, med mindre styret bestemmer noe annet. 9. Aksjer som ikke er fullt innbetalt, kan ikke overdras eller selges. 8. Aksjespleis og endring av Selskapets vedtekter Styrets forslag ble gjennomgått og vedtatt. Stemmeresultatet fremgår av protokollen. Generalforsamlingen fattet følgende <u>vedtak:</u> 8.1 Styrefullmakt til å utstede aksjer i forbindelse med aksjespleis Styret i IDEX Biometrics ASA ("Selskapet") gis fullmakt til å gjennomføre en kapitalutvidelse ved å utstede et antall aksjer med en total nominell verdi av NOK 0,99. Denne styrefullmakten er i tillegg til øvrige styrefullmakter i denne protokollen og i punkt 8.1 i protokollen fra ordinær generalforsamling i 2024. Fullmakten kan kun anvendes i forbindelse med aksjespleisen foreslått i punkt 8.2 og kun i den utstrekning det er nødvendig for å gjøre det samlede antall aksjer i Selskapet delelig på 100. Fullmakten omfatter ikke kapitalforhøyelse i forbindelse med fusjon etter allmennaksjeloven § 13-5. Nåværende aksjeeiere gir avkall på sine fortrinnsretter til å tegne aksjer i medhold av allmennaksjeloven § 10-4 i tilfelle en forhøyelse av aksjekapitalen i henhold til denne fullmakten.	6. The Extraordinary General Meeting authorizes the Board to amend the Company's Articles of Association concerning the size of the share capital and number of outstanding shares when the instant authorization is used. 7. The authorization shall be valid until 14 June 2025. 8. The new shares, which may be subscribed for according to this authorization, shall have right to dividends declared subsequent to the subscriber having paid the subscription price and the associated share capital increase having been registered in the Register of Business Enterprises. In other respects, the shares shall have shareholder rights from the time of issuance, unless the Board determines otherwise. 9. Shares that are not fully paid cannot be transferred or sold. 8. Share consolidation and amendment to the Company's Articles of Association The Board's proposal was reviewed and approved. The voting results are set out in these minutes. The general meeting passed the following <u>resolutions:</u> 8.1 Board authorization to issue shares in connection with share consolidation The Board of Directors of IDEX Biometrics ASA (the "Company") is authorized to carry out a share capital increase by issuing a number of shares with a total nominal value of NOK 0.99. This Board authorization is in addition to the Board authorizations in these minutes and in section 8.1 in the minutes from the 2024 Annual General Meeting. The authorization may be used only in connection with the share consolidation proposed in section 8.2 and solely to the extent necessary to make the total number of shares in the Company dividable by 100. The authorization does not comprise share capital increases in connection with mergers, cf. Section 13-5 in the PLCA. Existing shareholders waive their preemptive right to subscribe for shares according to Section 10-4 of the PLCA in event of a share capital increase as authorized herein.
---	--

Betaling av aksjekapital i forbindelse med en kapitalforhøyelse som det er gitt fullmakt til her, kan foretas ved tingsinnskudd og på andre måter som beskrevet i allmennaksjeloven § 10-2.

Fullmakten skal gjelde frem til 30. juni 2025.

De nye aksjene som kan tegnes i henhold til denne fullmakten, skal være berettiget til utbytte som besluttes utdelt etter at den tilhørende kapitalforhøyelsen er registrert i Foretaksregisteret. I andre henseender skal aksjene ha aksjeeierrettigheter fra utstedelsesdato, med mindre styret bestemmer noe annet.

8.2 Aksjespleis

Selskapets aksjer slås sammen slik at hundre (100) aksjer, hver pålydende NOK 0,01, slås sammen til én (1) aksje, pålydende NOK 1. Sammensetningen av Selskapets aksjekapital skal derfor endres fra 4 431 594 300 aksjer, hver pålydende NOK 0,01, til 44 315 943 aksjer, hver pålydende NOK 1,00 (ikke hensyntatt kapitalutvidelsen som er nødvendig for å gjøre det samlede antall aksjer i Selskapet delelig med 100 ved styrets bruk av fullmakten foreslått i agendapunkt 8.1, og forutsatt at Reparasjonsemisjonen tegnes fullt ut). Tallene skal justeres dersom det gjennomføres kapitalforhøyelser (utover Gjeldskonverteringen) i perioden mellom dato for denne innkalling og gjennomføringsdato for aksjespleisen, og/eller dersom Reparasjonsemisjonen ikke fulltegnes.

Aksjespleisen skal gjennomføres med virkning fra 11. juni 2025 eller på slikt senere tidspunkt som måtte fastsettes av styret.

Aksjonærer som ikke eier et antall aksjer som er delelig med 100, vil bli rundet opp vederlagsfritt, slik at de vil ha et antall som er delelig med 100, ved overføring av aksjer fra andre aksjonærer eller Selskapet. I den utstrekning opprunding av antall aksjer medfører at antallet utestående aksjer i VPS overstiger antallet registrerte aksjer i Selskapet, gis styret fullmakt til å slette de overskytende aksjene i VPS.

Som følge av aksjespleisen skal utestående tegningsretter og warrants justeres tilsvarende i henhold til de

Payment of share capital in connection with a share capital increase authorized herein may be made by way of non-cash contributions and other special subscription terms, as provided in Section 10-2 of the PLCA.

The authorization shall be valid until 30 June 2025.

The new shares, which may be subscribed for according to this authorization, shall have right to dividends declared subsequent to the associated share capital increase having been registered in the Register of Business Enterprises. In other respects, the shares shall have shareholder rights from the time of issuance, unless the Board determines otherwise.

8.2 Share consolidation

The Company's shares are consolidated so that a hundred (100) shares, each having a par value of NOK 0.01, are consolidated into one (1) share, having a par value of NOK 1. The composition of the Company's share capital shall therefore be changed from 4,431,594,300 shares, each having a par value of NOK 0.01, to 44,315,943 shares, each having a par value of NOK 1.00 (not taking into consideration the share capital increase necessary to make the total number of shares in the Company divisible by 100 by the Board's use of the authorization proposed in agenda item 8.1, and provided that the Subsequent Offering is fully subscribed for). These numbers shall be adjusted to the extent share capital increases (other than the Debt Conversion) are completed between the date of this notice and the execution date of the share consolidation, and/or if the Subsequent Offering is not fully subscribed for.

The share consolidation shall be carried out with effect from 11 June 2025 or such later date as determined by the Board.

Shareholders who do not own a number of shares that is divisible by 100 will be rounded upwards, free of charge, so that they have a number of shares divisible by 100, by way of transfer of shares from other shareholders or the Company. To the extent the rounding upwards of shares result in the number of outstanding shares in the VPS being in excess of the registered number of shares in the Company, the Board is authorized to delete such surplus shares in the VPS.

By reason of the share consolidation, outstanding incentive subscription rights and warrants shall be

justeringsklausuler som er vedtatt av Selskapets generalforsamlinger i forbindelse med godkjenning av de respektive tegningsrettsprogram og warrants i Selskapet. Utestående konvertible lån i Selskapet skal justeres slik at konverteringsprisen som skal betales for aksjer i Selskapet etterfølgende konvertering av slike konvertible lån, justeres tilsvarende spleisfaktoren.	adjusted accordingly, in accordance with the adjustment clauses resolved by the Company's general meeting in connection with the approval of the respective subscription rights incentive plans and warrants in the Company. Outstanding convertible loans in the Company shall be adjusted so that the conversion price to be paid for shares in the Company upon conversion of such convertible loans, shall be adjusted in accordance with the ratio of the share consolidation.
8.3 Endring av Selskapets vedtekter i anledning aksjespleisen Punkt 5 i Selskapets vedtekter endres til å lyde: <i>"Selskapets aksjekapital er NOK 44 315 943 fordelt på 44 315 943 aksjer á NOK 1 lydende på navn."</i> Dersom det gjennomføres kapitalforhøyelser før registrering av aksjespleisen eller dersom Reparasjonsemisjonen ikke tegnes fullt ut, har styret fullmakt til å endre vedtektene tilsvarende.	8.3 Amendment to the Company's Articles of Association in connection with the share consolidation Section 5 in the Company's Articles of Association shall be amended to read as follows: <i>"The Company's share capital is NOK 44,315,943 divided into 44,315,943 shares with a nominal value of NOK 1 per share and issued in name."</i> If share capital increases are carried out before registration of the share consolidation or if the Subsequent Offering is not fully subscribed for, the Board is authorized to amend the Articles of Association accordingly.
9. Godkjenning av nye konvertible obligasjoner som erstatter utestående konvertible obligasjoner utstedt 28. desember 2023 Styrets forslag ble gjennomgått og vedtatt. Stemmeresultatet fremgår av protokollen. Generalforsamlingen fattet følgende <u>vedtak:</u> Underlagt det følgende vedtak, har Selskapet vedtatt å terminere konvertible lån i Selskapet med en total pålydende verdi på NOK 100 000 000,00 (de "Opprinnelig Konvertible Lån"), som vedtatt av Selskapets styre 28. desember 2023 ("2023 Styrevedtak") i henhold til en styrefullmakt til opptak av konvertible lån. Lånet ble tegnet av CVI Investments, Inc. ("Långiver") og Selskapet og Långiver inngikk en obligasjonsavtale datert 22. desember 2023 ("Opprinnelig Obligasjonsavtalen"). I henhold til endrings- og omformuleringsavtalen av den Opprinnelige Obligasjonsavtalen mellom Långiver og Selskapet datert 6. november 2024 og en endrings- og omformuleringsavtale til den Opprinnelige Obligasjonsavtalen	9. Approval of new convertible bonds to replace outstanding convertible bonds issued on 28 December 2023 The Board's proposal was reviewed and approved. The voting results are set out in these minutes. The general meeting passed the following <u>resolution:</u> Subject to the following resolution, the Company resolves to terminate convertible loans in the Company with a total par value of NOK 100,000,000.00 (the "Original Convertible Loans"), as resolved by the Board of the Company on 28 December 2023 ("2023 Board Resolution") pursuant to a Board authorization to issue convertible loans. The Loan was subscribed for by CVI Investments, Inc. (the "Lender") and the Company and Lender entered into a Bond Agreement dated 22 December 2023 (the "Original Bond Agreement"). Pursuant to an amendment and restatement agreement to the Original Bond Agreement between the Lender and Company dated 6 November 2024 and an amendment and restatement agreement to the Original Bond

som skal inngås så snart det er praktisk mulig etter datoen for dette vedtaket (kollektivt "**Endrings- og Omformuleringsavtalene**"), og med forbehold om følgende vedtak og ytterligere forbeholdt at Långiver tegner seg for det Konvertible Lånet (som heretter definert) i samsvar med dette vedtaket, er de Opprinnelig Konvertible Lånene herved terminert.

Basert på vilkårene i den Opprinnelige Obligasjonsavtalen som endret av Endrings- og Omformuleringsavtalene (den "**Nye Obligasjonsavtalen**"), vedtar Selskapet herved å oppta nye konvertible lån i Selskapet med en total pålydende verdi på NOK 49 980 000,00 (de "**Konvertible Lån**").

De Konvertible Lån skal tegnes til en tegningspris tilsvarende NOK 49 980 000,00, og skal tegnes av CVI Investments, Inc. på en separat tegningsblankett innen 15. mai 2025.

Hvis Selskapet gjennomfører en etterfølgende kapitalinnhenting innen 31. desember 2025, skal hovedstolen på de utestående obligasjonene under de Konvertible Lån reduseres i samsvar med vilkårene i den Nye Obligasjonsavtalen (som, per datoen for denne innkallingen, vil resultere i en reduksjon av hovedstolen på obligasjonene til NOK 33 320 000,00).

Eksisterende aksjonærs fortrinnsrett etter allmennaksjeloven § 11-4 fravikes.

Betaling og utbetaling av de Konvertible Lån er allerede gjennomført i samsvar med betaling og utbetaling av de Opprinnelige Konvertible Lånene. De Opprinnelige Konvertible Lån vil bli konvertert til de Konvertible Lån, og Selskapet skal ikke motta noen ytterligere innbetalinger fra Långiver i forbindelse med de Konvertible Lån.

De Konvertible Lån skal ikke være rentebærende.

De Konvertible Lån forfaller og skal tilbakebetales (med mindre de Konvertible Lån helt eller delvis har blitt konvertert til aksjer) senest 28. desember 2027 ("**Endelig Forfallsdato**"). De Konvertible Lån amortiseres fra (og inkludert) 28. juni 2026 og på ethvert seks måneders jubileum deretter, som avsluttes på (og inkludert) Endelig Forfallsdato. Hver utestående obligasjon vil bli innløst over fire like avdrag til et beløp tilsvarende NOK 124,950 per obligasjon, med mindre obligasjonene reduseres i samsvar med vilkårene i den Nye Obligasjonsavtalen. Långiver skal

Agreement to be entered into as soon as reasonably practicable after the date of these resolutions (the "**Amendment and Restatement Agreements**"), and subject to the following resolutions and further subject to the Lender having subscribed to the Convertible Loans (as hereinafter defined) in accordance with these resolutions, the Original Convertible Loans are hereby terminated.

Based on the terms of the Original Bond Agreement as amended by the Amendment and Restatement Agreements (the "**New Bond Agreement**"), the Company hereby resolves to issue new convertible loans in the Company with a total par value of NOK 49,980,000.00 (the "**Convertible Loans**").

The Convertible Loans shall be subscribed for at a subscription price of NOK 49,980,000.00, and shall be subscribed for by CVI Investments, Inc. on a separate subscription form within 15 May 2025.

If the Company carries out a subsequent equity raise by no later than 31 December 2025, the principal amount of the Bonds outstanding under the Convertible Loans shall be subject to reduction in accordance with the terms of the New Bond Agreement (which, as of the date of this notice, would result in the reduction of the aggregate principal amount under the Bonds to NOK 33,320,000.00).

The existing shareholders' preferential rights pursuant to Section 11-4 of the PLCA are deviated from.

Payment and disbursement of the Convertible Loans has already been made in accordance with the payment and disbursement of the Original Convertible Loans. The Original Convertible Loans will be converted into the Convertible Loans, and the Company shall not receive any additional payments from the Lender in connection with the Convertible Loans.

The Convertible Loans shall not bear any interest.

The Convertible Loans matures and shall be repaid (unless the Convertible Loans or part thereof has been converted into shares) no later than 28 December 2027 (the "**Final Maturity Date**"). The Convertible Loans shall amortize from (and including) 28 June 2026 and on each six-month anniversary thereof ending on (and including) the Final Maturity Date. Each Bond outstanding will be redeemed across four equal instalments of NOK 124,950 per Bond, unless reduced in accordance with the terms of the New Bond Agreement. The Lender shall

ikke lenger ha rett til å be om amortiserte betalingsforskudd. De Konvertible Lån kan konverteres til aksjer i selskapet senest på Endelig Forfallsdato.

Långiver skal fra (og med) 1. september 2025 til (og inkludert) datoen som faller to Oslo-virkedager før Endelig Forfallsdato ha rett til å konvertere de Konvertible Lån, helt eller delvis, forutsatt at den til enhver tid gjeldende markedsprisen (som definert i den Nye Obligasjonavtalen) på en aksje er NOK 0,10 eller mer (slik terskel er underlagt visse justeringsbestemmelser i den Nye Obligasjonavtalen), skal Långiver ha rett til å konvertere alle eller deler av de Konvertible Lån så lenge denne prisen opprettholdes. Selskapet skal på hver avdragsdato ha rett til å tilbakebetale avdraget kontant eller ved konvertering til aksjer på konverteringsprisen beskrevet nedenfor.

Ved konvertering av alle eller deler av de Konvertible Lån til aksjer, skal konverteringsprisen beregnes som følger:

Konverteringsprisen skal være NOK 0.065 per aksje ("**Konverteringsprisen**"). Långiver har gått med på å frskrive seg sine rettigheter under den Opprinnelige Obligasjonavtalen om å tilbakestille Konverteringsprisen i tilfelle gjennomføringen av en Kvalifisert Kapitalinnhenting. Reduksjon av pålydende verdi på aksjene fra NOK 0.15 til NOK 0.01, utstedelsen av eventuelle nye aksjer i henhold til Gjeldskonverteringen som angitt i agendapunkt 4 i denne EGF eller enhver utstedelse av nye aksjer eller salg av eksisterende aksjer tidligere eid av Selskapet eller et datterselskap eller tilknyttet selskap (i hvert tilfelle unntatt ved utøvelse av rettigheter til konvertering til, eller bytte eller tegning for, eller retten til å på annen måte erverve aksjer knyttet til eventuelle Equity-Linked Rights (som heretter definert)); eller (b) enhver utstedelse av andre verdipapirer (inkludert, men ikke uttømmende listet opp, warrants, opsjoner eller andre rettigheter til å tegne for eller kjøpe eller erverve aksjer eller andre aksjer i Selskapets kapital) eller annen rett som ved dets utstedelsesvilkår har (direkte eller indirekte) rettigheter til konvertering til, eller bytte eller tegning for, eller retten til å på annen måte erverve aksjer (slike verdipapirer eller rettigheter, "**Equity-Linked Rights**"), skal ikke føre til en justering i forhold til Konverteringsprisen.

Bortsett fra som beskrevet i forrige avsnitt, skal de Konvertible Lån gi full anti-utvanningsbeskyttelse og inneholde standard konverteringskursjusteringer ved gjennomføring av visse selskaphendelser, som

no longer have the right to request amortized payment advances. The Convertible Loans may at the latest be converted to shares in the Company on the Final Maturity Date.


The Lender shall from (and including) 1 September 2025 to (and including) the date falling two Oslo business days prior to the Final Maturity Date have the right to convert the Convertible Loans, in whole or in part, provided that if, at any time the Current Markets price (as defined in the New Bond Agreement) of a Share is NOK 0.10 or more (such threshold being subject to certain adjustment provisions in the New Bond Agreement), the Lender shall be permitted to convert all or part of the Convertible Loans for so long as such price is maintained. The Company shall on each instalment date have the right to repay the instalment in cash or by conversion into shares on the conversion price described below.

In case of conversion of all or part of the Convertible Loans into shares, the conversion price shall be calculated as follows:

The conversion price shall be NOK 0.065 per share ("**Conversion Price**"). The Lender has agreed to waive its rights under the Original Bond Agreement to reset the Conversion Price in case of a Qualified Equity Raise. The reduction of par value of the shares from NOK 0.15 to NOK 0.01, the issue of any new shares pursuant to the Debt Conversion as set forth in agenda item 4 at this EGM or any issuance of new shares or any sale of existing shares previously held by the Company or any subsidiary or affiliate of the Company (in each case other than upon exercise of rights of conversion into, or exchange or subscription for, or the right to otherwise acquire, any shares attached to any Equity-Linked Rights (as hereinafter defined)); or (b) any issuance of any other securities (including without limitation warrants, options or other rights to subscribe for or purchase or acquire shares or any other shares in the capital of the Company) or other right which by their terms of issue carry (directly or indirectly) rights of conversion into, or exchange or subscription for, or the right to otherwise acquire, any shares (any such securities or rights, "**Equity-Linked Rights**"), shall not cause an adjustment to occur in respect of the Conversion Price.


Except as otherwise described in the preceding paragraph, the Convertible Loans shall provide full anti-dilution protection and contain standard conversion rate adjustments upon the occurrence of certain events, like

utbyttebetalinger, distribusjoner, aksjesplitt, kvalifiserte utstedelser av aksjer eller andre instrumenter i selskapet eller kombinasjoner, og en standardformel for midlertidig redusering av den gjeldende konverteringsprisen ved forekomst av en «change of control» i Selskapet (for å kompensere for den delen som konverteringsperioden blir forkortet med i tilfelle konvertering ved en slik endring av kontroll på Selskapet).	dividend payments, distributions, share splits, qualified issues of shares or other instruments in the Company or combinations and a standard formula for temporarily lowering the current conversion price upon the occurrence of a change of control (to compensate for the proportion by which the conversion period is cut short in the case of conversion upon a change of control in the Company).
Konverteringsprisen skal i alle tilfeller ikke være lavere enn summen av pålydende verdi på Selskapets aksje. Det høyeste beløpet aksjekapitalen kan økes med ved konvertering av de Konvertible Lån, er NOK 49 980 000,00 (forutsatt at pålydende verdi på Selskapets aksjer reduseres til NOK 0.01).	The Conversion Price shall under no circumstances be lower than the sum of the par value of the Company's share. The highest amount the share capital can be increased with by conversion of the Convertible Loans, is NOK 49,980,000.00 (provided that the par value of the Company's shares is reduced to NOK 0.01).
Tegningsrettighetene skal ikke kunne skilles fra fordringen og utnyttes uavhengig av denne.	The subscription rights cannot be separated from the accounts receivable and be used independently thereof.
Aksjeinnskuddet skal dekkes mot at fordringen under de Konvertible Lån nyttes til motregning.	The share contribution shall be settled by set-off of the accounts receivable under the Convertible Loans.
De Konvertible Lån (eller deler av dem) kan overdras av Långiver uten skriftlig forhåndssamtykke fra Selskapets styre.	The Convertible Loans (or parts thereof) may be assigned by the Lender without the advance written approval by the Board of Directors of the Company.
Långiver skal ha aksjonærrettigheter (inkludert rett til utbytte) fra det tidspunktet notifikasjon om utøvelse av konverteringsretten er mottatt av Selskapet, og fra samme tidspunktet skal aksjene utstedt ved konvertering registreres i Selskapets aksjeeierregister. Hvis Selskapet før Endelig Forfallsdato beslutter forhøyelse eller nedsetting av aksjekapitalen, nytt opptak av lån etter allmennaksjeloven § 11-1 følgende, eller øvrige utstedelse av tegningsretter iht. allmennaksjelovens kapittel 11, eller ved oppløsning, fusjon eller fisjon, skal Långiver ha samme rettigheter som en aksjonær (Långiver vil imidlertid ikke ha stemmerett i forhold til lånet før konvertering til aksjer).	The Lender shall have shareholder rights (including dividend rights) from the time the notification of exercise of the conversion right is received by the Company and from the same time the shares issued upon conversion shall be registered in the Company's shareholder register. If, before the Final Maturity Date, the Company decides to increase or decrease the share capital, obtain new borrowing pursuant to section 11-1 of the PLCA, issue subscription rights pursuant to chapter 11 of the PLCA, or by dissolution, merger or demerger, the Lender shall have the same rights as a shareholder (however, the Lenders will not have voting rights in regard to the loan until conversion into shares).
Avskrift av seneste årsregnskap, årsberetning og revisjonsberetning er utlagt på Selskapets kontor.	Copies of the latest annual accounts, the annual report and the auditor's report is available at the Company's offices.
Opptak av Lånet og den foreslåtte gjennomføringen av Gjeldskonverteringen, Kapitalnedsettelsen og aksjespleisen, godkjenning av det Konvertible Lånet (som heretter definert), og endringen i Selskapets forretningsstrategi og ledelse (som annonsert av Selskapet den 11. mars 2025) er alle hendelser etter siste balansedag som er ansett å være av vesentlig betydning for Selskapet. Utenom dette har det ikke inntruffet hendelser etter siste balansedag som er av vesentlig betydning for Selskapet.	The obtaining of the Loans and the proposed performing of the Debt Conversion, Share Capital Reduction and share consolidation, approval of the Convertible Loans (as hereinafter defined), and change of business strategy and executive management in the Company (as announced by the Company on 11 March 2025), are all considered events since the latest balance date which is deemed to significantly impact the Company. Other than this, there have not been any events since

Det forelå ingen flere saker.
Generalforsamlingen ble deretter hevet

Morten Opstad
styreleder

the latest balance date which significantly impacts the Company.

No other items were on the agenda.
The general meeting was subsequently adjourned.


Kristian Flaten
Medundertegner/Co-signer

Vedlegg 1 / Appendix 1: Fremmøtte aksjonærer / Shareholders present

Totalt representert /
Attendance Summary Report
IDEX Biometrics ASA
Ekstraordinær Generalforsamling / EGM
11 April 2025

Antall personer deltakende i møtet /	13
Registered Attendees:	
Totalt stemmeberettiget aksjer representert	268,077,252
/ Total Votes Represented:	
Totalt antall kontoer representert /	44
Total Accounts Represented:	
 Totalt stemmeberettiget aksjer /	 831,461,991
Total Voting Capital:	
% Totalt representert stemmeberettiget /	32.24%
% Total Voting Capital Represented:	
Totalt antall utstede aksjer / Total Capital:	831,594,232
% Totalt representert av aksjekapitalen / % Total Capital	32.24%
Represented:	
Selskapets egne aksjer / Company Own Shares:	132,241

Sub Total: 9 4 268,077,252

<u>Kapasitet / Capacity</u>	<u>Registrerte Deltakere /</u> <u>Registered Attendees</u>	<u>Registrerte Ikke-Stemmeberettigede</u> <u>Deltakere / Registered Non-Voting</u>		<u>Kontoer /</u> <u>Accounts</u>
		<u>Attendees</u>	<u>/ Registered Votes</u>	
Aksjonær / Shareholder (web)	6	0	5,174,730	6
Gjest / Guest (web)	0	4		
Forhåndsstemmer / Advance votes	1	0	118,443,827	7
Styrets leder med fullmakt / COB with Proxy	1	0	143,958,601	29
Styrets leder med instruksjoner / COB with Instruc	1	0	500,094	2

Martin Bråten
DNB Bank ASA
Issuer services

Vedlegg / Appendix 2: Stemmeoversikt / Voting overview

IDEX Biometrics ASA EKSTRAORDINÆR GENERALFORSAMLING / EGM 11 April 2025

Som registreringsansvarlig for avstemmingen på generalforsamlingen for aksjonærene i selskapet avholdt den 11 April 2025, BEKREFTES HERVED at resultatet av avstemmingen er korrekt angitt som følger:-

/

As scrutineer appointed for the purpose of the Poll taken at the General Meeting of the Members of the Company held on 11 April 2025, I HEREBY CERTIFY that the result of the Poll is correctly set out as follows:-

Totalt antall stemmeberettigede aksjer / Issued voting shares: 831,461,991

	STEMMER / VOTES FOR	%	STEMMER / VOTES MOT / AGAINST	%	STEMMER / VOTES AVSTÅR / WITHHELD	STEMMER TOTALT / VOTES TOTAL	% AV STEMME- BERETTIG KAPITAL AVGITT STEMME / % ISSUED VOTING SHARES VOTED	IKKE AVGITT STEMME I MØTET / NO VOTES IN MEETING
1	267,577,158	100.00	0	0.00	500,094	268,077,252	32.24%	0
2	267,877,158	100.00	0	0.00	200,094	268,077,252	32.24%	0
3,1	267,777,252	99.89	300,000	0.11	0	268,077,252	32.24%	0
3,2	267,762,104	99.88	314,420	0.12	728	268,077,252	32.24%	0
3,3	267,762,104	99.88	314,420	0.12	728	268,077,252	32.24%	0
4,1	267,762,104	99.88	314,420	0.12	728	268,077,252	32.24%	0
4,2	267,762,104	99.88	314,420	0.12	728	268,077,252	32.24%	0
5	268,062,104	99.99	14,420	0.01	728	268,077,252	32.24%	0
6a	267,576,430	99.81	500,094	0.19	728	268,077,252	32.24%	0
6b	267,876,430	99.93	200,094	0.07	728	268,077,252	32.24%	0
7	267,862,010	99.92	215,242	0.08	0	268,077,252	32.24%	0
8,1	267,577,158	99.81	500,094	0.19	0	268,077,252	32.24%	0
8,2	267,577,158	99.81	500,094	0.19	0	268,077,252	32.24%	0
8,3	267,577,158	99.81	500,094	0.19	0	268,077,252	32.24%	0
9	267,862,738	99.99	14,420	0.01	200,094	268,077,252	32.24%	0

Martin Bråten
DNB Bank ASA
Issuer services

Attendance Details

Page: 1
Date: 11 Apr 2025
Time: 12:36

Meeting: IDEX Biometrics ASA, AGM 11 April 2025

	<u>Attendees</u>	<u>Votes</u>
Aksjonær / Shareholder	6	5,174,730
Gjest / Guest	4	
Forhåndsstemmer / Advance votes	1	118,443,827
Styrets leder med fullmakt / COB with Proxy		143,958,601
Styrets leder med instruksjoner / COB with in		500,094
Total	13	268,077,252

Aksjonær / Shareholder 6 5,174,730

	<u>Votes</u>	<u>Representing / Accompanying</u>	<u>Voting Card</u>
DOBBER CORPORATION AS, Rep. ved Morten Opstad	33,070	DOBBER CORPORATION AS, Rep. ved Morten Opstad. 1504778	
K-KONSULT AS, Rep. ved Morten Opstad	594,514	K-KONSULT AS, Rep. ved Morten Opstad. 1493576	
MARC O POLO NORGE AS, Rep. ved Morten Opstad	1,692,630	MARC O POLO NORGE AS, Rep. ved Morten Opstad. 1492099	
OPSTAD, MORTEN	153,788	OPSTAD, MORTEN. 1497411	
POTINGA, VASILE DANUT	728	POTINGA, VASILE DANUT. 1535004	
TVETEN, CHRISTIAN RUST	2,700,000	TVETEN, CHRISTIAN RUST. 1491828	

Gjest / Guest 4

	<u>Votes</u>	<u>Representing / Accompanying</u>	<u>Voting Card</u>
netha, nikhil			
netha, nikki			
peter, john			
Svela, Erling			

Forhåndsstemmer / Advance vc 1 118,443,827

	<u>Votes</u>	<u>Representing / Accompanying</u>	<u>Voting Card</u>
Forhåndsstemmer / Advance votes	31,018,728	DNB FUND - DISRUPTIVE OPPORTUNITIES. 1570050R	
	5,000,000	CHARLES STANLEY AND CO LTD. 1570068R	
	81,524,779	Spreadex Ltd. 1570076R	
	870,700	Keith, Robert. 1570084R	
	14,420	SPDR PORTFOLIO EUROPE ETF. 1570092R	
	200	CYNTHIA A JOHNSON R/O IRA VFTC AS. 1570100R	
	15,000	REAL PROPERTY INTERNATIONAL LIMITED. 1570118R	
	118,443,827		

Styrets leder med fullmakt / CO 1 143,958,601

	<u>Votes</u>	<u>Representing / Accompanying</u>	<u>Voting Card</u>
Styrets leder med fullmakt / COB with Proxy	67,337,255	ALTEA AS. 1491406R	
	30,491,498	SUNDT AS. 1491422R	
	21,641,605	RAGNVALD GABRIELSEN AS. 1491430R	
	9,558,248	SUNDVALL HOLDING AS. 1491505R	
	5,700,000	LANGNÆS, LARS ESPEN. 1491554R	
	3,000,000	STORBRATEN, ANDERS. 1491760R	
	1,600,639	SKORPION AS. 1492115R	
	1,287,137	BREDLAND, LARS THOMAS. 1492131R	
	1,000,000	TAANEVIG, KJELL MICHAEL. 1492693R	
	1,000,000	FLATEN, KRISTIAN. 1492750R	
	400,000	BIG TOP HOLDING AS. 1494327R	
	180,120	JOHANSEN, TRULS NORDBY. 1496785R	
	157,950	BØE, MARIANNE. 1497361R	
	135,000	PINCHCLIFFE AS. 1497940R	
	125,844	SVELA, ERLING. 1498161R	
	106,992	A. SUNDVALL INVEST AS. 1498583R	
	106,000	RUSTAD, EINAR. 1498625R	
	65,000	LINDAHN, STIG KRISTIAN. 1501303R	
	24,152	LARSEN, SVEIN. 1506591R	
	21,500	FILTHY RICH AS. 1507219R	
	8,670	SUNDVALL, RUNE. 1514058R	
	4,900	HALAND, MORTEN PEDER. 1518802R	
	4,000	SUND, STEVE MORGAN. 1520287R	
	1,000	SVENSEN, GLENN MORTEN. 1531417R	
	400	REBBESTAD, HELGE STIG. 1540202R	
	400	WIKAN, SIW. 1540665R	
	204	FAGERHOL, GEIR IVAR. 1544782R	
	67	NICOLAYSEN, JØRGEN SCHØYEN. 1553833R	
	20	GUNDERSEN, LARS SCHEID. 1559608R	

Attendance Details

Page: 2
Date: 11 Apr 2025
Time: 12:36

143,958,601

Styrets leder med instruksjoner 1

500,094

Styrets leder med instruksjoner / COB with instructions

<u>Votes</u>	<u>Representing / Accompanying</u>
300,000	DALBAKK, AGNAR JAN OLAUS. 1494962R
200,094	RUFA'I, JEYLANI ABUKAR. 1496033R
<u>500,094</u>	

Voting Card





IDEX BIOMETRICS ASA
PARENT COMPANY INTERIM STATEMENT OF FINANCIAL POSITION
(Norwegian: “Mellombalanse”)

January 1, 2025

This interim statement of financial position (Norwegian: “mellombalanse”) has been prepared for the purpose of a proposed share capital reduction.

The proposal will be considered by the extraordinary general meeting of shareholders in the company on April 11, 2025.

The document is filed with the Norwegian Register of company accounts. This statement and other public information about IDEX Biometrics ASA are available at the company’s web site www.idexbiometrics.com.

The company’s disclosures to the market and the general public are available at Oslo Børs’s web sites live.euronext.com/en or www.newspoint.no.

References included in this document or other documents are intended as an aid to where information can be found and the documents referenced are not incorporated by reference into this document unless explicitly stated.

The instant interim statement of financial position has been prepared by using principles for recognition and measurement that are consistent with the standards applied in the annual financial statements of the company.

Date of issue: March 21, 2025

IDEX Biometrics ASA
Dronning Eufemias gate 16, NO-0191 Oslo, Norway
+47 6783 9119; mailbox@idexbiometrics.com www.idexbiometrics.com
Corp. ID: NO 976 846 923 MVA/VAT

IDEX Biometrics ASA
Parent Company Interim Statements of Financial Position
(In USD thousands, except share numbers and per share amounts)

		As of	
	Note	Jan 1, 2025	Dec 31, 2023
Assets			
Non-current assets:			
Goodwill	4	\$ —	\$ 968
Intangible assets	4	569	1 011
Property, plant and equipment	5	14	303
Right-of-use assets		15	39
Shares in subsidiaries	1, 10	452	1 749
Non-current receivables		7	7
Total non-current assets		1 058	4 077
Current assets:			
Prepaid expenses		660	463
Inventory	8	5 548	6 384
Accounts receivable, other	6	274	525
Accounts receivable, trade	6	30	1 068
Receivables from group companies	6	2 403	10 366
Cash and cash equivalents		1 921	10 818
Total current assets		10 837	29 625
Total assets		\$ 11 894	\$ 33 701

The accompanying notes are an integral part of this interim statement of financial position.

		As of	
	Note	Jan 1, 2025	Dec 31, 2023
Equity and liabilities			
Share capital (NOK 0.15 par value per share, 831,576,974 and 1,397,010,650 shares issued and outstanding at January 1, 2025 and December 31, 2023, respectively)	9	\$ 12 942	\$ 25 955
Share premium		1 735	2 118
Share-based payment	9	25 210	24 858
Capital reduction reserves		321 264	300 500
Accumulated loss		(360 485)	(337 510)
Total equity		666	15 922
Non-current liabilities:			
Non-current lease liabilities		—	13
Total non-current liabilities		—	13
Current liabilities:			
Accounts Payable		754	721
Payables to group companies		6 468	6 794
Current lease liabilities		4	19
Public duties payable		67	89
Interest-bearing loans	7	1 983	5 076
Other current financial liabilities	7	791	3 545
Other current liabilities		1 161	1 522
Total current liabilities		11 228	17 766
Total liabilities		11 228	17 780
Total equity and liabilities		\$ 11 894	\$ 33 701

The accompanying notes are an integral part of this interim statement of financial position.

March 21, 2025

The board of directors of IDEX Biometrics ASA

/s/ Morten Opstad
Morten Opstad
Chair

/s/ Annika Olsson
Annika Olsson
Board member

/s/ Adriana Saitta
Adriana Saitta
Board member

/s/ Anders Storbråten
Anders Storbråten
CEO

IDEX Biometrics ASA
Parent Company Interim Statements of Changes in Equity
(In USD thousands)

	Share capital	Share premium	Share- based payment	Foreign currency translation effects	Capital reduction reserve	Accumulated loss	Total equity
Balance at January 1, 2023	\$ 22 762	\$ 4 036	\$ 23 576	\$ —	\$ 287 500	\$ (312 369)	\$ 25 505
Share issuance	3 128	11 009	—	—	—	—	14 137
Share-based compensation	65	73	1 283	—	—	—	1 421
Loss for the year	—	—	—	—	—	(25 141)	(25 141)
Transfer of share premium	—	(13 000)	—	—	13 000	—	—
Other comprehensive income	—	—	—	—	—	—	—
Balance at December 31, 2023	\$ 25 955	\$ 2 118	\$ 24 858	\$ —	\$ 300 500	\$ (337 510)	\$ 15 922
Share capital reduction	(20 764)	—	—	—	20 764	—	—
Share issuance	7 616	(774)	—	—	—	—	6 842
Conv. bond settled in shares	130	391	—	—	—	—	521
Share-based compensation	5	—	351	—	—	—	356
Loss for the period	—	—	—	—	—	(22 976)	(22 976)
Other comprehensive income	—	—	—	—	—	—	—
Balance at January 1, 2025	<u>\$ 12 942</u>	<u>\$ 1 735</u>	<u>\$ 25 210</u>	<u>\$ —</u>	<u>\$ 321 264</u>	<u>\$ (360 485)</u>	<u>\$ 666</u>

The accompanying notes are an integral part of this interim statement of financial position.

K

ca

NOTES TO PARENT COMPANY INTERIM STATEMENT OF FINANCIAL POSITION

1. Organization

IDEX Biometrics ASA, is the parent company of the IDEX Group. The company's shares are listed on Euronext Oslo Børs under ticker symbol IDEX. Also warrants A&B are listed at Euronext Oslo Børs under ticker symbols IDEXJ and IDEXS, cf. note 9—*Share capital and share premium, warrants and incentive subscription rights*.

IDEX Biometrics ASA has wholly-owned subsidiaries in the United States (IDEX Biometrics Holding Company Inc. and IDEX Biometrics America Inc.), the United Kingdom (IDEX Biometrics UK Ltd.), and China (IDEX Electronics (Shanghai) Co., Ltd.). The parent company is the owner of all intellectual property of IDEX and is the contractual party to all customer and manufacturing partner agreements. All sales are generated by the parent company, and the parent company is the supplier to the customers. The subsidiaries provide various services to the parent company, mainly associated with engineering, supply-chain administration, and customer service functions. IDEX Biometrics UK Ltd. has also developed intellectual property (IP) on its own account and risk, which IP IDEX Biometrics ASA has the right of first refusal to purchase at arm's length terms. As of the date of this interim statement of financial position, there is very little or no activity in the subsidiaries in the USA and China.

2. Basis of preparation and accounting principles

This interim statement of financial position (Norwegian: "*mellombalanse*") for IDEX Biometrics ASA, the parent company in the IDEX Biometrics group, has been prepared for the purpose of a proposed share capital reduction.

This interim statement of financial position has been prepared by using principles for recognition and measurement that are consistent with the standards applied in the annual financial statements of the company, viz. IFRS Accounting Standards as adopted by the EU. There have not been any changes to IDEX Biometrics ASA's accounting policies applied in preparation of this interim statement of financial position compared to those applied in the annual financial statements for 2023. For the avoidance of doubt, the instant interim statement of financial position does not constitute a report that is compliant with IFRS.

This interim statement of financial position as of January 1, 2025 was approved by the board on March 21, 2025.


3. Going concern

The going concern assumption has been applied in the preparation of the interim statement of financial position. Going concern assumes the realization of assets and liquidation of liabilities in the normal course of business. IDEX Biometrics has incurred significant operating losses and negative cash flows during the development stage of the business. Net equity amounted to \$0.7 million, less than half the share capital, and the balance sheet solvency was negative as of January 1, 2025. During 2024, the Company implemented measures to significantly reduce staff and operating expenses, mainly in the technical functions in the US and China, while maintaining the customer support functions and supply chain capabilities. The existing cash does not fund the Company's operating expenses and capital expenditures requirements for the next twelve months.

While the Company has been successful in the past in raising funds through private placements of shares and issuance of convertible debt, there is no assurance that IDEX Biometrics will be successful in raising capital in the future.

On March 11, 2025, the company disclosed that following a strategic review, concluding that the company shall concentrate its technical and commercial efforts on serving the access market, where IDEX is believed to possess competitive advantage. IDEX Biometrics will seek to also harvest from its long-time efforts in the payment market. On the same date, the company disclosed that it had received irrevocable undertakings from certain existing shareholders and new investors to lend NOK 30 million (\$2.8 million) to fund the commercialization efforts in line with the revised business strategy.

Further, an extraordinary general meeting will be held on April 11, 2025 when the board will propose, i.a. to (i) reduce the share capital of IDEX Biometrics ASA by decreasing the par value per existing share from NOK 0.15 per share to NOK 0.01 per share, and (ii) subject to completion of the Share Capital Decrease, convert the loans to shares at a subscription price per share equal to NOK 0.01 per share. The lenders have undertaken to subscribe for shares and settle the share contribution by debt conversion. The board will also propose a



subsequent offering of shares at the same price to the other existing shareholders, raising up to NOK 6 million (\$0.6 million). These actions will cover the company's immediate cash needs.

Thirdly, the company disclosed that it had entered into a commitment letter and term sheet for an amendment agreement with the holder of the company's convertible bonds amounting to NOK 67 million (\$6.3 million) whereby the terms of the convertible bond will be amended such that, inter alia, (i) the principal amount will be reduced by 25%, and, (ii) subject to the company obtaining additional equity on market terms by December 31, 2025, the principal amount would be reduced by a further 25%. Certain other terms of the bonds were also amended.

In the short term, the IDEX Biometrics is dependent on the successful implementation of the foregoing. The long-term future viability depends on the company's ability to generate cash from operating activities and to raise additional capital to finance its operations. IDEX Biometrics's existing cash and the funding described above is not sufficient to fund its operating expenses and capital expenditures requirements for the next twelve months. While the company has been successful in the past in raising funds through private placements of shares and issuance of convertible debt, there is no assurance that IDEX Biometrics will be successful in raising capital the future. The company's failure to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategies. These factors cast significant doubt on IDEX Biometrics's ability to continue as a going concern.

As an ongoing activity, IDEX Biometrics monitors liquidity and is prepared to take appropriate measures if and when required. IDEX has been successful in the past with implementing cost reductions and raising capital through private placements of equity. Reflecting the recent funding described above and acknowledging the significant doubt, the board has on balance concluded that the conditions for the going concern assumption are met.

4. Goodwill and other intangible assets

<i>Amounts in \$1,000</i>	Goodwill	Acquired patents	Total
Carrying amount at December 31, 2023	\$ 968	\$ 1 011	\$ 1 979
Amortization and impairment	(968)	(442)	(1 410)
Carrying amount at December 31, 2024	\$ —	\$ 569	\$ 569

There is only one cash generating unit (CGU) in the company and goodwill is allocated to this. IDEX performed an annual impairment test on January 1, 2025. Based on the impairment test, it was determined that the book value exceeded the recoverable amount. Accordingly, an impairment charge of \$968 thousand was recorded.

Acquired identifiable intangible assets, consisting primarily of patents, are held at cost, less accumulated amortization and impairment charges. Acquired patents are capitalized and amortized over the estimated useful life, which is the lifetime of the respective patent(s). As of January 1, 2025, and December 31, 2023, the value of the patents was deemed to not be impaired.

5. Property, plant and equipment

Tangible fixed assets are comprised of scientific and test equipment, engineering tools, leasehold improvements, office equipment, and furniture with useful lives of three to seven years. In connection with the closing of the activities in IDEX America and IDEX China, right-to-use/leasehold assets were discontinued.

The strategic change disclosed on March 11, 2025, did not per se represent a reason for impairment.

A recent change in the relation with a manufacturing partner is expected to lead to disuse and disposal of equipment held by IDEX Biometrics ASA that is placed at the partner's facility. To reflect lower of net book value and value in use, an impairment charge amounting to USD 156k was recognized as of January 1, 2025.

6. Accounts receivable

Accounts receivable, trade, includes invoiced amounts due from customers. The receivables are stated at the estimated realizable value.

Accounts receivable, other, consist primarily of governments support to approved research and development projects and value added tax refund.

In an arbitration ruling at Oslo Chamber of Commerce on January 27, 2025, in favor of IDEX Biometrics, the company was awarded \$0.7 million from customer Zwipe AS, plus late payment interest and compensation for

the Company's legal costs. On March 6, 2025, the Oslo District Court ruled that bankruptcy proceedings for Zwiipe shall take place. IDEX Biometrics continues to pursue any recoverable value, but the receivable has been written off in the interim statement of financial position as of January 1, 2025.

Expected credit loss accrued for as of January 1, 2025, was \$849 thousand, and \$144 thousand at the end of 2023.

No group or other receivables than customer accounts receivables were overdue as of January 1, 2025 or at the end of 2023. A significant share of the receivables from group companies is related to IDEX UK. IDEX UK operated at a loss in 2023 but was profitable in 2024. IDEX UK is not expected to eventually repay the full receivable. IDEX Biometrics ASA has estimated IDEX UK's planned activity level going forward to determine the probable recoverable amount. An impairment charge amounting to \$4,4 million has been made to the receivable as of January 1, 2025. See note 10—*Subsidiaries*.

7. Convertible debt

<i>Amounts in USD 1,000</i>	Interest rate	Amortization	Carrying value
Convertible bond as of Dec. 31, 2023	6%	Bimonthly until June 28, 2027	
Convertible debt			\$ 5 076
Embedded derivative			3 545
Total			\$ 8 621
Convertible bond as of Jan. 1, 2025	0%	Semi-annual from Jun. 28, 2026 to Dec. 28, 2027	
Convertible debt			\$ 1 984
Embedded derivative			139
Total			\$ 2 123

In December 2023, IDEX Biometrics entered into a convertible debt financing agreement. The agreement has later been amended, see below. The company issued NOK 100 million, or \$9.9 million in convertible bonds at 6.0% interest p.a. The loan is denominated in NOK. IDEX Biometrics received NOK 92 million after deduction of the issue discount. Transactions and balance amounts are reported in USD at the exchange rates at the respective dates. The bond holder could elect to convert the outstanding loans into IDEX shares at any time prior to repayment at a conversion price of NOK 3.655, when taking into account the 5:1 share consolidation (reverse split) effective on record date January 10, 2024.

The conversion option is accounted for as an embedded derivative and was recognized separately as a financial liability at fair value through profit or loss. The host contract is recognized at amortized cost, a residual after deduction of transaction costs and the embedded derivative. The effective interest rate is based on the value of the host contract and the expected cash flow. Because the company does not have an unconditional right to defer payment beyond twelve months, both the host contract and the embedded derivative were classified as current liabilities as of December 31, 2023.

Estimation methods are used to determine the fair value of the embedded derivative. There is a significant element of judgment in the estimation methods used and the assumptions applied.

Under the original agreement, the debt would be redeemed in 21 equal bi-monthly instalments of NOK 4.8 million plus accrued interest. The lender could request up to two additional instalments to be paid in each period between the planned term dates. The company may elect to settle the interest payments, principal payments, or both with shares in lieu of cash. Any repayment in shares will be converted at 90% of the prevailing market price of the shares.

On September 17, 2024, IDEX Biometrics entered into a commitment letter to amend the terms of the convertible bond. The full agreement was entered into on November 6, 2024. The coupon interest rate on the bond was reduced to 0%. The repayment will be in four semi-annual terms starting from June 28, 2026, extending the duration of the loan until December 28, 2027. The conversion rate on the loan was reduced to NOK 0.85 per share. Conversion can, at the earliest, be done on February 28, 2026, unless the share price exceeds NOK 1.25 after June 28, 2025. The Company may elect to settle the principal payments with shares in lieu of cash payments. Any repayment in shares will be converted at 90% of the prevailing market price of the shares. The amendment represented a substantial modification of the financial liability under IFRS 9. The original host contract and embedded derivative was therefore derecognised and the amended debt was recognised at fair value of the host contract and the embedded derivative. This resulted in a gain on modification, reducing the recognised value of the instruments.

As of January 1, 2025, the outstanding principal amount was NOK 66,640,000.

On March 10, 2025, IDEX Biometrics and Heights entered into a commitment letter whereby the terms of the convertible bond will be amended. The amendment has not been reflected in the valuation of the convertible debt as of January 1, 2025. See note 11—*Subsequent events*.

8. Inventory

Inventories consist of raw materials, work in process, and finished goods. Materials and components purchased for use in research and development activities are expensed at the time of purchase. Inventory is recorded at the lower of cost and net realizable value, net of selling costs. Virtually all material and components in inventory are bespoke to IDEX and its products. It is not realistic to return to suppliers or find alternative outlets.

Amounts in \$1,000	January 1, 2025			December 31, 2023		
	Cost	Reserves	Net	Cost	Reserves	Net
Raw materials	\$ 3 876	\$ (705)	\$ 3 171	\$ 3 795	\$ —	\$ 3 795
Work in progress	36	—	36	102	—	102
Finished goods	3 107	(765)	2 342	3 356	(869)	2 487
Total	\$ 7 019	\$ (1 470)	\$ 5 548	\$ 7 253	\$ (869)	\$ 6 384

IDEX disclosed on March 11, 2025, a strategic shift to focus on the access market, while seeking to also harvest from its long-time efforts in the payment market. Consequently, parts of the material and components held in inventory are less likely to be sold, and an obsolescence provision has been recognized.

The quantity of certain components (raw material) in inventory is substantially larger than what is required for the current business plan. Some of the inventory may remain unused and unsold by the time the material becomes obsolete because of aging/shelf life and/or technical obsolescence. Any such obsolescence will depend on, among other factors, technical development, and the timing is uncertain. Based on an assessment with horizon three years derived from the current business plan and estimated usage, an impairment charge has been recognized as of January 1, 2025.

9. Share capital and share premium, warrants and incentive subscription rights

There is one class of shares, and all shares have equal rights and are freely negotiable. The share capital is fully paid in. The par value of the shares was NOK 0.15 per share on January 1, 2025. IDEX does not beneficially own any of its own shares.

A 5:1 share consolidation (reverse split) took effect on record date January 10, 2024. The incentive subscription rights plans have adjustment clauses so that the number of subscription rights and the exercise prices were adjusted by the same ratio. The par value of the shares was NOK 0.15 per share before the consolidation, and NOK 0.75 per share after the consolidation. On February 26, 2024, the share capital was written down, and the par value again NOK 0.15 per share. The reduction amount was transferred to Capital reduction reserve to cover uncovered losses.

During the year ended December 31, 2023, \$13.0 million of Share Premium was transferred to Capital Reduction Reserve, to cover uncovered losses. The transfer did not impact the total equity. No such transfer was made since December 31, 2023.

<i>Number of instruments</i>	Shares	Warrants	Incentive subscription rights
Balance at December 31, 2022	1 166 326 584		81 106 631
Share issues (Employee Share Purchase Plan)	4 583 947		
Share issue (exercise of incentive subscription rights)	389 608		(389 608)
Private placement of Shares on May 24	116 897 492		
Private placement of Shares on June 16	30 161 332		
Private placement of Shares on November 16	78 651 685		
Private placement of Shares on December 22	2		
Net granted and expired/forfeited subscription rights			14 117 639
Balance at December 31, 2023	1 397 010 650	—	94 834 662
Consolidation (5:1) on January 10	279 402 130	—	18 966 932
Share issues (Employee Share Purchase Plan)	358 525		
Share issue (exercise of incentive subscription rights)	365 900		(532 572)
Private placement of Shares on May 15	27 940 213	27 940 213	
Private placement of Shares on June 19	5 393 120	5 393 120	
Private placement of Shares on August 20	16 166 667	—	
Convertible loan term payment settled in shares on August 20	9 123 333		
Private placement of Shares on September 16	101 624 966	101 624 966	
Private placement of Shares on October 14	365 041 700	365 041 700	
Private placement of Shares on December 2	26 160 420	26 160 420	
Net granted and expired/forfeited subscription rights			4 135 505
Balance at January 1, 2025	831 576 974	526 160 419	22 569 865

IDEX Biometrics has awarded subscription rights to shares to employees and individual contractors. The weighted average exercise price of outstanding incentive subscription rights on January 1, 2025, was NOK 3.41 per share.

In connection with private placements in 2024, subscribers to new shares were also allocated warrants with vesting dates in 2025. The warrants issued in May and June, 2024 ("May warrants") and in September-December, 2024 ("Warrants A" and "Warrants B" or, collectively, "Warrants A&B", have exercise prices of NOK 0.65 and NOK 0.15 per share, respectively. The May warrants are exercisable in quarterly windows after issue of interim reports and expire fourteen days after the interim report for the first quarter of 2025 has been issued. Warrants A are exercisable within the first 14 days following the disclosure the preliminary financial statements for 2024, viz. from February 2025 to February 13, 2025, and Warrants B are exercisable from March 31, 2025, to April 11, 2025. The warrants will lapse unless exercised within the respective periods. 17,258 warrants A were exercised in the period February 28-March 13, 2025.

<i>Amounts in USD 1,000</i>	Exercise price	Expiry	Carrying value
Warrants May-Jun	NOK 1.65	May 29, 2025	\$ 1
Warrants A	NOK 0.15	March 13, 2025	326
Warrants B	NOK 0.15	April 11, 2025	326
Total			\$ 652

The warrants were recognized on the respective issue dates as a financial liability denominated in NOK, at fair value through profit and loss. The valuation at initial recognition was based on option calculations. The original recognized value of the May warrants amounted to NOK 19.7 million or \$1.9 million, and the warrants A and B combined NOK 34.7 million or \$3.2 million. The warrants are valued at fair value at each balance sheet date. The May warrants are valued by option calculations while the Warrants A&B are listed on Euronext Oslo Børs and valued at market. 17,258 warrants A with exercise price NOK 0.15 per share were exercised in the period February 28-March 13, 2025. See note 11—*Subsequent events*.

10. Subsidiaries

The subsidiaries are 100% owned by IDEX Biometrics ASA. The subsidiaries provide various services to the parent company, mainly within technical development, supply-chain administration and customer interface, and marketing and sales facilitation services to IDEX Biometrics ASA. The subsidiaries do not have independent trade or business. The accounting year in all subsidiaries is the calendar year, same as in IDEX Biometrics ASA.

The subsidiaries are held in IDEX Biometrics ASA's statement of financial position at amortised cost. If the value of the subsidiary for any reason is determined to be lower than the amortised cost, a corresponding impairment charge has been recognised in order to not overvalue the subsidiary.

Amounts in \$1,000

Jan. 1, 2025	Ownership and votes	Carrying value
IDEX Biometrics Holding Co. Inc., Delaware, USA	100%	1
IDEX Biometrics America Inc., Delaware, USA	100%	—
IDEX Biometrics UK Ltd., England	100%	2 373
IDEX Electronics (Shanghai) Co., Ltd, China	100%	443
Dec. 31, 2023		
IDEX Biometrics Holding Co. Inc., Delaware, USA	100%	1
IDEX Biometrics America Inc., Delaware, USA	100%	—
IDEX Biometrics UK Ltd., England	100%	9 990
IDEX Electronics (Shanghai) Co., Ltd, China	100%	1 741

IDEX Biometrics Holding Company Inc. (IDEX Holding) is a holding company for the activities in the USA. The operating company, IDEX Biometrics America Inc. (IDEX America), is held by IDEX Holding. IDEX America ceased virtually all of its operation during the first half of 2024 and vacated its facilities. At the date of this interim statement of financial position there is negligible activity. IDEX Biometrics ASA has not injected share capital or made other investments in IDEX Holding but owed \$5,718 thousand to IDEX America as of January 1, 2025.

Due to losses in prior years, IDEX Biometrics UK Ltd. (IDEX UK) had negative equity as of January 1, 2025. IDEX Biometrics ASA has provided funding as needed. IDEX UK has earned income from (1) provision of services to IDEX ASA priced at cost-plus, and (2) creating relevant IP in fingerprint technology, and selling such IP to IDEX Biometrics ASA at negotiated price. Going forward, IDEX UK is expected to primarily provide services in mode (1). The value has been written down to a level that can be justified by IDEX UK's planned activity and realistic profit margin.

IDEX Electronics (Shanghai) Co., Ltd. (IDEX China) ceased its operation during December 2024, and vacated its facilities. As of the date of this interim statement of financial position, IDEX China is in the process of being dissolved. IDEX Biometrics ASA has injected a share capital in IDEX China amounting to \$1,741 thousand, and has an accounts payable balance of \$443k to IDEX China. On the dissolution date, the only asset held by IDEX China will be the receivable from IDEX Biometrics ASA. Consequently, IDEX Biometrics ASA has written down its investment in IDEX China by \$1,298.

11. Subsequent events

In an arbitration ruling at Oslo Chamber of Commerce on January 27, 2025, in favor of IDEX Biometrics, the company was awarded \$0.7 million from customer Zwipe AS, plus late payment interest and compensation for the Company's legal costs. On March 6, 2025, the Oslo District Court ruled that bankruptcy proceedings for Zwipe shall take place. The receivable has been written off in the interim statement of financial position as of January 1, 2025. See note 6—*Accounts receivable*.

Effective March 11, 2025, Anders Storbråten was appointed CEO of IDEX Biometrics ASA.

IDEX Biometrics disclosed on March 11, 2025, a revised strategy and a bridge funding amounting to NOK 30 million (\$2.8 million) to fund the activities in line with the revised business strategy. See note 3—*Going concern*. The revised strategy has been taken into consideration when valuing the inventory as of January 1, 2025. See note 8—*Inventory*. The bridge funding did not have any effect on the recognized value of IDEX Biometrics ASA's assets or liabilities as of January 1, 2025.

Also on March 11, 2025, IDEX Biometrics disclosed that the company had entered into a commitment letter whereby the terms of its outstanding convertible bonds were amended. The amended terms do not cause a change in the liability of the convertible bonds as of January 1, 2025. The amendments included, inter alia, that (i) the principal amount of the Bonds will be reduced by 25%, (ii) subject to the Company's consummation of any further equity raise on market terms latest December 31, 2025, the principal amount of the Bonds would be reduced by a further 25%, (iii) the conversion period shall be the period from September 1, 2025 to two Oslo business days prior to the Final Maturity Date, December 28, 2027. If the market price of the share in the Company is NOK 0.10 or more, the Bondholder shall be permitted to exercise its Conversion Rights under the Bonds for so long as such price is maintained, (iv) the conversion price is reset to be NOK 0.065, (v) any provisions under the Bonds relating to the Bondholder's rights to exercise Amortised Payment Advancements

shall not apply. The amendments to the Convertible Bond will be subject to approval by the extraordinary general meeting of the company on April 11, 2025. The amendment represents a substantial modification of the financial liability under IFRS 9. The host contract and embedded derivative (as previously amended) will therefore be derecognised and the amended debt will be recognised at fair value of the host contract and the embedded derivative as of March 10, 2025. This is expected to result in a gain on modification, reducing the recognised value of the instruments.

17,258 warrants A with exercise price NOK 0.15 per share were exercised in the period February 28-March 13, 2025. The warrants are presented in note 9—*Share capital and share premium, Warrants*. Following the exercise and issue of shares, the Company's share capital is NOK 124,739,134.80, divided into 831,594,232 shares each with a nominal value of NOK 0.15]

There have been no other events between January 1, 2025, and the date of this interim statement of financial position that have had any material impact on the value of IDEX Biometrics ASA's assets and liabilities as of January 1, 2025.



REPORT OF INDEPENDENT AUDITOR



Shape the future
with confidence

Statsautoriserte revisorer
Ernst & Young AS

Thormøhlens gate 53 D, NO-5008 Bergen
Postboks 6163, NO-5892 Bergen

Foretaksregisteret: NO 976 389 387 MVA
Tlf: +47 24 00 24 00

www.ey.com/no
Medlemmer av Den norske revisorforening

INDEPENDENT AUDITOR'S REPORT

To the Annual General Meeting in IDEX Biometrics ASA

Auditor's report on interim statement of financial position ("mellombalans")

Opinion

We have audited the accompanying interim statement of financial position of IDEX Biometrics ASA as at January 1, 2025, showing an equity of TUSD 666. The interim statement of financial position s comprises the financial positions and notes to interim statement of financial position. The interim statement of financial position is prepared by the Board and CEO by applying the accounting principles described in note 2 to the interim statement of financial position

In our opinion, interim statement of financial position presents fairly, in all material respects, the financial position of the Company as at January 1, 2025, in accordance with accounting principles described in note 2 to the interim statement of financial position

Basis for opinion

We conducted our audit in accordance with laws, regulations, and auditing standards and practices generally accepted in Norway, including the International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the interim balance sheet* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the interim balance sheet in Norway, and we have fulfilled our ethical responsibilities as required by law and regulations. We have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Basis for the interim statement of financial position and limited distribution

We draw attention to note 2 to the interim statement of financial position, describing the basis for the preparation. As the interim statement of financial position has been prepared to enable IDEX Biometrics ASA to carry out a capital reduction, it is not considered suitable for other purposes.

Material uncertainty related to going concern

We would like to draw attention to Note 3 in the interim statement of financial position. As outlined in the Notes, the Company has experienced substantial losses and negative cash flows from its operations. These circumstances, along with other matters described therein, indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Management's responsibility for the interim statement of financial position

Management (the Board and the CEO) is responsible for the preparation of this interim statement of financial position as described in note 2 and for such internal control as management determines is necessary to enable the preparation of the interim balance sheet that is free from material misstatement, whether due to fraud or error.

In preparing the interim statement of financial position, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going



Shape the future
with confidence

concern and using the going concern basis of accounting, unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the interim statement of financial position

Our objectives are to obtain reasonable assurance about whether the interim statement of financial position is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an

audit conducted in accordance with law, regulations and generally accepted auditing principles in Norway, including International Standards on Auditing (ISAs) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this interim balance sheet.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- ▶ identify and assess the risks of material misstatement of the interim balance sheet, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- ▶ obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control;
- ▶ evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- ▶ conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the interim financial position or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;
- ▶ evaluate the overall presentation, structure and content of the interim balance sheet, including disclosures, and whether the interim balance sheet represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Bergen, March 21, 2025
ERNST & YOUNG AS

The auditor's report is signed electronically

Trine Hansen Bjerkvik
State Authorized Public Accountant (Norway)

Auditor's report for the interim statement of financial position of IDEX Biometrics ASA

A handwritten signature in blue ink, appearing to be 'Trine Hansen Bjerkvik', is located in the bottom right corner of the page.

Vedlegg 2/Appendix 2

<u>Lender</u>	<u>Loan amount</u>
Altea AS	kr 2 875 000
Anders Storbråten	kr 8 625 000
Andreas Holding AS	kr 1 400 000
Charles Street International Holding Ltd	kr 10 000 000
Christian Rust Tveten	kr 400 000
Jakob Iqbal	kr 300 000
Lars Langnæs	kr 450 000
Littlehammer Capital AS	kr 200 000
Morten Opstad	kr 500 000
Oliva Holding AS	kr 300 000
Ragnvald Gabrielsen AS	kr 900 000
R. Sundvall Invest AS	kr 500 000
Skorpio AS	kr 800 000
Svein Hatleskog	kr 750 000
Sundt AS	kr 2 000 000
Total:	kr 30 000 000

4 W

